Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag for Chemotherapy-Induced Thrombocytopenia
CTR20192192Phase 3Terminated
- Sponsor
- Dova Pharmaceuticals, Inc.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of avatrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Dova Pharmaceuticals, Inc.. Started Nov 2019; status: terminated.
02
Drugs
avatrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20192192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192192.